Citations

Mayo Clinic

Showing 10 of 108599 citations.

Sirt6 deficiency results in progression of glomerular injury in the kidney
Huang, Wen, Liu, Hua , Zhu, Shuang , Woodson, Michael , Liu, Rong , Tilton, Ronald G. , Miller, Jordan D. , Huang, Wen, Zhang, Wenbo , Miller, Jordan

Aging | March 28, 2017 | Volume: 9 | Issue: 3 | Pages: 1069-1083

10.18632/aging.101214 | PMID 28351995 Get It

Frequency, Predictors, and Implications of Abnormal Blood Pressure Responses During Dobutamine Stress Echocardiography
Abram, S.E., Arruda‐Olson, Adelaide M. , Pellikka, Patricia A. , Oh, Jae K. , Milan, Alberto , Abidian, Mohamed Modar , McCully, Robert B. , Abram, Sara, Abidian, Mohamed M, Scott, Christopher G. , Nkomo, Vuyisile T. , Pellikka, Patricia A

Circulation: Cardiovascular Imaging | March 28, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circimaging.116.005444 | PMID 28351907 Get It

Background— It is not known whether abnormal blood pressure (BP) responses during dobutamine stress echocardiography (DSE) are associated with abnormal test results, nor if such results indicate obstructive coronary artery disease (CAD). We sought to define the frequency of abnormal BP responses during DSE and their impact on accuracy of test results. Methods and Results— We studied 21 949 patients who underwent DSE at Mayo Clinic, Rochester, MN, grouped by peak systolic BP achieved during the test. We also analyzed a subgroup who underwent coronary angiography within 30 days after positive DSE. The positive predictive value of DSE was calculated for each BP group. Patients with hypertensive response (n=1905; 9%) were more likely to have positive DSE than those with normal (n=19 770; 90%) or hypotensive (n=274; 1%) BP responses (32% versus 21% versus 23%, respectively; P <0.0001). Angiography, performed in 1126 patients, showed obstructive CAD (≥50% stenosis) in 814 patients and severe CAD (≥70% stenosis) in 708 patients. Positive predictive value of DSE was similar for patients who had hypertensive and normal BP responses (69% versus 73%; P =0.3), considering 50% stenosis cut point. The proportion of severe CAD (≥70% stenosis) was lower in patients who had hypertensive response compared with those who had normal BP response (54% versus 65%; P =0.005). Conclusions— Patients with hypertensive response during DSE are more likely to have stress-induced myocardial ischemia compared with those with normal or hypotensive BP responses but are not more likely to have false-positive DSE results. They are, however, less likely to have higher grade or multivessel CAD.
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Sepulveda, Antonia R. , Allegra, Carmen J. , Grody, Wayne W., Cushman‐Vokoun, Allison M. , Funkhouser, William K., Kopetz, Scott , Lindor, Noralane M. , Minsky, Bruce D. , Monzon, Federico A. , Singh, Veena , Clark, Jennifer , Colasacco, Carol , Temple‐Smolkin, Robyn , Ventura, Christina B., Nowak, Jan A. , Hamilton, Stanley R. , Grody, Wayne, Cushman-Vokoun, Allison M, Kopetz, Scott E, Singh, Veena M, Temple-Smolkin, Robyn, Lieu, Christopher H. , Sargent, Daniel J. , Willis, Joseph , Rumble, R. Bryan , Kopetz, Scott

Journal of Oncology Practice | March 28, 2017 | Volume: 13 | Issue: 5 | Pages: 333-337

10.1200/jop.2017.022152 | PMID 28350513 Get It

Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model
Dalela, Deepansh , Santiago‐Jiménez, María , Yousefi, Kasra, Karnes, R. Jeffrey , Ross, Ashley E. , Den, Robert B. , Freedland, Stephen J. , Schaeffer, Edward M. , Dicker, Adam P. , Menon, Mani, Briganti, Alberto , Abdollah, Firas , Davicioni, Elai , Den, Robert B , Dicker, Adam P

Journal of Clinical Oncology | March 28, 2017 | Volume: 35 | Issue: 18 | Pages: 1982-1990

10.1200/jco.2016.69.9918 | PMID 28350520 Get It

Purpose Despite documented oncologic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate cancer is still limited in the United States. We aimed to develop and internally validate a risk-stratification tool incorporating the Decipher score, along with routinely available clinicopathologic features, to identify patients who would benefit the most from aRT. Patient and Methods Our cohort included 512 patients with prostate cancer treated with radical prostatectomy at one of four US academic centers between 1990 and 2010. All patients had ≥ pT3a disease, positive surgical margins, and/or pathologic lymph node invasion. Multivariable Cox regression analysis tested the relationship between available predictors (including Decipher score) and clinical recurrence (CR), which were then used to develop a novel risk-stratification tool. Our study adhered to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis guidelines for development of prognostic models. Results Overall, 21.9% of patients received aRT. Median follow-up in censored patients was 8.3 years. The 10-year CR rate was 4.9% vs. 17.4% in patients treated with aRT versus initial observation ( P < .001). Pathologic T3b/T4 stage, Gleason score 8-10, lymph node invasion, and Decipher score > 0.6 were independent predictors of CR (all P < .01). The cumulative number of risk factors was 0, 1, 2, and 3 to 4 in 46.5%, 28.9%, 17.2%, and 7.4% of patients, respectively. aRT was associated with decreased CR rate in patients with two or more risk factors (10-year CR rate 10.1% in aRT v 42.1% in initial observation; P = .012), but not in those with fewer than two risk factors ( P = .18). Conclusion Using the new model to indicate aRT might reduce overtreatment, decrease unnecessary adverse effects, and reduce risk of CR in the subset of patients (approximately 25% of all patients with aggressive pathologic disease in our cohort) who benefit from this therapy.
Reducing Pediatric Sternal Wound Infections: A Quality Improvement Project
Delgado‐Corcoran, Claudia , Dorn, Charlotte S. Van , Pribble, Charles G., Thorell, Emily A., Pavia, Andrew T. , Ward, Camille, Smout, Randall J., Bratton, Susan L. , Burch, Phillip T., Ward, Camille

Pediatric Critical Care Medicine | March 28, 2017 | Volume: 18 | Issue: 5 | Pages: 461-468

10.1097/pcc.0000000000001135 | PMID 28350561 Get It

Objectives: To evaluate whether a quality improvement intervention reduces sternal wound infection rates in children after cardiac surgery. Design: This is a pre- and postintervention quality improvement study. Setting: A 16-bed cardiac ICU in a university-affiliated pediatric tertiary care children’s hospital. Patients: All patients undergoing cardiac surgery via median sternotomy from January 2010 to December 2014 are included. The sternal wound infection rates for primary closure and delayed sternal closure are reported per 100 sternotomies. The hospital-acquired infection records were used to identify preintervention cases, while postintervention cases were collected prospectively. Intervention: Implementation of a sternal wound prevention bundle during the preoperative, intraoperative, and postoperative periods for cardiac surgical cases. Measurements and Main Results: During the preintervention period, 32 patients (3.8%) developed sternal wound infection, whereas only 19 (2.1%) developed sternal wound infection during the postintervention period (p = 0.04). The rates of sternal wound infection following primary closure were not significantly different pre- and postintervention (2.4% vs 1.6%; p = 0.35). However, patients with delayed sternal closure had significantly lower postintervention infection rates (10.6% vs 3.9%; p = 0.02). Conclusions: Implementation of a sternal wound prevention bundle during the perioperative period was associated with lower sternal wound infection rates in surgeries with delayed sternal closure.
Monocytosis in polycythemia vera: Clinical and molecular correlates
Barraco, Daniela , Cerquozzi, Sonia , Gangat, Naseema , Patnaik, Mrinal M. , Finke, Christy M. , Hanson, Curtis A. , Ketterling, Rhett P. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

American Journal of Hematology | March 28, 2017 | Volume: 92 | Issue: 7 | Pages: 640-645

10.1002/ajh.24740 | PMID 28370365 Get It

AbstractMonocytosis (absolute monocyte count, AMC ≥ 1 × 109/L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in polycythemia vera (PV). Among 267 consecutive patients with World Health Organization (WHO)‐defined PV, 55 (21%) patients displayed an AMC of ≥1 × 109/L and 18 (7%) an AMC of ≥1.5 × 109/L. In general, PV patients with monocytosis were significantly older and displayed higher frequencies of leukocytosis (81% vs. 50% at AMC ≥1 × 109/L) and TET2/SRSF2 mutations (57%/29% vs. 19%/1% at AMC ≥ 1.5 × 109/L). In univariate analysis, AMC ≥1.5 × 109/L adversely affected overall (OS; P = .004; HR 2.6, 95% CI 1.4‐4.8) and myelofibrosis‐free (MFFS; P = .02; HR 4.4, 95% CI 1.3‐15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P = .05) and MFFS (P = .06). Other independent risk factors for OS included unfavorable karyotype (P = .02, HR 3.39, 95% CI 1.17‐9.79), older age (P < .0001, HR 3.34 95% CI 1.97‐5.65), and leukocytosis ≥15 × 109/L (P = .004, HR 2.04, 95% CI 1.26‐3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.
The US Preventive Services Task Force Recommendation on Screening for Asymptomatic Celiac Disease
Choung, Rok Seon , Murray, Joseph A. , Choung, Rok Seon

JAMA | March 28, 2017 | Volume: 317 | Issue: 12 | Pages: 1221

10.1001/jama.2017.1105 | PMID 28350906 Get It

Precision Medicine—Right Treatment, Right Patient, Right Time, Wrong Approach?
Mills, John R.

Clinical Chemistry | March 28, 2017 | Volume: 63 | Issue: 4 | Pages: 928-929

10.1373/clinchem.2016.267963 | PMID 28351859 Get It

Wnt/β‐Catenin Signaling Activates Expression of the Bone‐Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types
Vega, Oscar A., Lucero, Claudia, Araya, Héctor, Jerez, Sofía , Tapia, Julio C. , Antonelli, Marcelo , Salazar‐Onfray, Flavio , Heras, Facundo Las, Thaler, Roman , Riester, Scott M. , Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J, Galindo, Mario A , Stein, Gary S. , van Wijnen, Andre J

Journal of Cellular Biochemistry | March 28, 2017 | Volume: 118 | Issue: 11 | Pages: 3662-3674

10.1002/jcb.26011 | PMID 28370561 Get It

ABSTRACTOsteosarcoma is the most common malignant bone tumor in children and adolescents. Metastasis and poor responsiveness to chemotherapy in osteosarcoma correlates with over‐expression of the runt‐related transcription factor RUNX2, which normally plays a key role in osteogenic lineage commitment, osteoblast differentiation, and bone formation. Furthermore, WNT/β‐catenin signaling is over‐activated in osteosarcoma and promotes tumor progression. Importantly, the WNT/β‐catenin pathway normally activates RUNX2 gene expression during osteogenic lineage commitment. Therefore, we examined whether the WNT/β‐catenin pathway controls the tumor‐related elevation of RUNX2 expression in osteosarcoma. We analyzed protein levels and nuclear localization of β‐catenin and RUNX2 in a panel of human osteosarcoma cell lines (SAOS, MG63, U2OS, HOS, G292, and 143B). In all six cell lines, β‐catenin and RUNX2 are expressed to different degrees and localized in the nucleus and/or cytoplasm. SAOS cells have the highest levels of RUNX2 protein that is localized in the nucleus, while MG63 cells have the lowest RUNX2 levels which is mostly localized in the cytoplasm. Levels of β‐catenin and RUNX2 protein are enhanced in HOS, G292, and 143B cells after treatment with the GSK3β inhibitor SB216763. Furthermore, small interfering RNA (siRNA)‐mediated depletion of β‐catenin inhibits RUNX2 expression in G292 cells. Thus, WNT/β‐catenin activation is required for RUNX2 expression in at least some osteosarcoma cell types, where RUNX2 is known to promote expression of metastasis related genes. J. Cell. Biochem. 118: 3662–3674, 2017. © 2017 Wiley Periodicals, Inc.
Ways to Write a Milestone: Approaches to Operationalizing the Development of Competence in Graduate Medical Education
Reed, Darcy A. , Starr, Stephanie R. , Havyer, Rachel D. , Lang, Tara R., Norby, Suzanne M. , Leep Hunderfund, Andrea N, Hunderfund, Andrea N. Leep

Academic Medicine | March 28, 2017 | Volume: 92 | Issue: 9 | Pages: 1328-1334

10.1097/acm.0000000000001660 | PMID 28353504 Get It

Purpose To identify approaches to operationalizing the development of competence in Accreditation Council for Graduate Medical Education (ACGME) milestones. Method The authors reviewed all 25 “Milestone Project” documents available on the ACGME Web site on September 11, 2013, using an iterative process to identify approaches to operationalizing the development of competence in the milestones associated with each of 601 subcompetencies. Results Fifteen approaches were identified. Ten focused on attributes and activities of the learner, such as their ability to perform different, increasingly difficult tasks (304/601; 51%), perform a task better and faster (171/601; 45%), or perform a task more consistently (123/601; 20%). Two approaches focused on context, inferring competence from performing a task in increasingly difficult situations (236/601; 29%) or an expanding scope of engagement (169/601; 28%). Two used socially defined indicators of competence such as progression from “learning” to “teaching,” “leading,” or “role modeling” (271/601; 45%). One approach focused on the supervisor’s role, inferring competence from a decreasing need for supervision or assistance (151/601; 25%). Multiple approaches were often combined within a single set of milestones (mean 3.9, SD 1.6). Conclusions Initial ACGME milestones operationalize the development of competence in many ways. These findings offer insights into how physicians understand and assess the developmental progression of competence and an opportunity to consider how different approaches may affect the validity of milestone-based assessments. The results of this analysis can inform the work of educators developing or revising milestones, interpreting milestone data, or creating assessment tools to inform milestone-based performance measures.